EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Multizentrische StudieOpen Access

CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease

Akshay Sharma iD, Jaap-Jan Boelens iD, Maria Cancio, Jane S Hankins, Prafulla Bhad, Marjohn Azizy, Andrew Lewandowski, Xiaojun Zhao, Shripad Chitnis, Radhika Peddinti, Yan Zheng, Neena Kapoor und 10 weitere

New England Journal of Medicine · 2023

DOI: 10.1056/nejmoa2215643 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Akshay Sharma und 21 weiteren Autor:innen. Beteiligte Einrichtung: From St. Jude Children's Research Hospital, Memphis, TN (A.S., J.S.H., Y.Z.); Memorial Sloan Kettering Cancer Center, New York (J.-J.B., M.C.); the N…. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Erythrocytes, Fetal Hemoglobin. Die Arbeit wurde bisher 187-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCRISPR-Cas SystemsErythrocytesFetal HemoglobinHematopoietic Stem Cell TransplantationAnimalsMiceAntigens, CD34Hemoglobin, SicklePromoter Regions, GeneticHumans

Substanzen

Antigens, CD34Fetal HemoglobinHemoglobin, Sickle

Autor:innen und Institutionen

  • From St. Jude Children's Research Hospital, Memphis, TN (A.S., J.S.H., Y.Z.); Memorial Sloan Kettering Cancer Center, New York (J.-J.B., M.C.); the Novartis Institutes for BioMedical Research, Cambridge, MA (P.B., M.A.,…

ORCID-Profile: Akshay Sharma, Jaap-Jan Boelens

Förderung

  • NCI NIH HHS
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Sharma, A., Boelens, J. J., Cancio, M., Hankins, J. S., Bhad, P., Azizy, M., Lewandowski, A., Zhao, X., Chitnis, S., Peddinti, R., Zheng, Y., Kapoor, N., Ciceri, F., Maclachlan, T., Yang, Y., Liu, Y., Yuan, J., Naumann, U., Yu, V. W. C., …, & LaBelle, J. L. (2023). CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2215643

Vancouver

Sharma A, Boelens JJ, Cancio M, Hankins JS, Bhad P, Azizy M, et al. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2215643

BibTeX
@article{Sharma2023,
  author = {Sharma, Akshay and Boelens, Jaap-Jan and Cancio, Maria and Hankins, Jane S and Bhad, Prafulla and Azizy, Marjohn and Lewandowski, Andrew and Zhao, Xiaojun and Chitnis, Shripad and Peddinti, Radhika and Zheng, Yan and Kapoor, Neena and Ciceri, Fabio and Maclachlan, Timothy and Yang, Yi and Liu, Yi and Yuan, Jianping and Naumann, Ulrike and Yu, Vionnie W C and Stevenson, Susan C and De Vita, Serena and LaBelle, James L},
  title = {CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease},
  journal = {New England Journal of Medicine},
  year = {2023},
  doi = {10.1056/nejmoa2215643}
}
Kostenlos starten →